Implementation of backward induction for sequentially adaptive clinical trials

Journal of Computational and Graphical Statistics

Volumn 15, Issue 2, 2006, Pages 398-413

  Wathen, J Kyle ^a   Christen, J Andrés ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b CENTRO DE INVESTIGACIÓN EN MATEMÁTICAS   (Mexico)

Author keywords

Bayesian sequential analysis; Decision theory; Dynamic programming

Indexed keywords

EID: 33745322898     PISSN: 10618600     EISSN: None     Source Type: Journal    
DOI: 10.1198/016214506X113406     Document Type: Article

References (17)

1. Barber, S., and Jennison, C. (2002), "Optimal Asymmetric One-sided Group Sequential Tests," Biometrika, 89, 49-60.
2. Berger, J. O. (1985), Statistical Decision Theory and Bayesian Analysis, New York: Springer-Verlag.
3. Berry, D. A., and Eick, S. (1995), "Adaptive Assignment Versus Balanced Randomization in Clinical Trials: A Decision Analysis," Statistics in Medicine, 14, 231-246.
4. Berry, D. A., and Ho, C.-H. (1988), "One-Sided Sequential Stopping Boundaries for Clinical Trials: A Decision-theoretic Approach," Biometrics, 44, 219-227.
5. Brockwell, A. E., and Kadane, J. B. (2003), "A Gridding Method for Sequential Analysis," Journal of Computational and Graphical Statistics, 12, 566-584.
6. Christen, J. A., Müller, P., Wathen, J. K., and Wolf, J. (2004), "A Bayesian Randomized Clinical Trial: A Decision Theoretic Sequential Design," Canadian Journal of Statistics, 32, 1-16.
7. Christen, J. A., and Nakamura, M. (2003), "Sequential Stopping Rules for Species Accumulation," Journal of Agricultural, Biological and Environmental Statistics, 8, 184-195.
8. DeGroot, M. H. (1970). Optimal Statistical Decisions, New York: McGraw-Hill.
9. Bales, J. D., and Jennison, C. (1992), "An Improved Method for Deriving Optimal One-sided Group Sequential Tests," Biometrika, 79, 13-24.
10. Estey, E., Thail, P., Cortes, J. E., Giles, F. J., O'Brien, S., Pierce, S. A., Wang, X., Kantarjian, H. M., and Beran, M. (2001), "Comparison of Idarubicin + Ara-C-, Fludarabine + Ara-C-, and Topotecan+Ara-C-based Regimens in Treatment of Newly Diagnosed AML, RAEB-T, or RAEB," Blood, 98, 3575-3583.
11. Kadane, J., and Vlachos, P. (2002), "Hybrid Methods for Calculating Optimal Few-Stage Sequential Strategies: Data Monitoring for a Clinical Trial," Statistics and Computing, 12, 147-152.
12. Lewis, R. J., and Berry, D. A. (1994), "Group Sequential Clinical Trials: A Classical Evaluation of Bayesian Decision-theoretic Designs," Journal of the American Statistical Association, 89, 1528-1534.
13. Müller, P., Berry, D. A., Grieve, A., Smith, M., and Krams, M. (1999), "Simulation-Based Sequential Bayesian Designs," available online at http://ftp.stat.duke.edu/WorkingPapers/99-29.htmt.
14. Stallard, N. (2003), "Decision-Theoretic Designs for Phase II Clinical Trials Allowing for Competing Studies," Biometrics, 59, 402-409.
15. Stallard, N., Thall, P. F., and Whitehead, J. (1999), "Decision Theoretic Designs for Phase II Clinical Trials With Multiple Outcomes," Biometrics, 55, 971-977.
16. Thall, P. F., Champlin, R. E., and Andersson, B. E. (2004), "Comparison of 100-Day Mortality Rates Associated With IV Busulfan and Cyclophosphamide Versus Other Preparative Regimens in Allogeneic Bone Marrow Transplantation for Chronic Myelogenous Leukemia: Bayesian Sensitivity Analyses of Confounded Treatment and Center Effects," Bone Marrow Transplantation, 33, 1191-1199.
17. Thall, P. F., Simon, R., and Estey, E. H. (1995), "New Statistical Strategy for Monitoring Safety and Efficacy in Single-Arm Clinical Trials," Journal of Clinical Oncology, 14, 296-303.